Trials & Filings

Alkermes Receives MMF Patent

Expects to begin trials of MS prodrug in mid-2014

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

The United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application 14/032,736, entitled “Prodrugs of fumarates and their use in treating various diseases,” to Alkermes. The allowed composition-of-matter claims will cover Alkermes’ MMF prodrug, ALKS 8700, a proprietary, small-molecule prodrug of monomethyl fumarate (MMF) for the treatment of multiple sclerosis. The Notice of Allowance resulted from a prioritized examination granted by the USPTO, and...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters